Phase 2Recruiting
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
Prospective, Randomized, Phase II Trial of Modified Short-Course Radiotherapy Plus CAPOX and Tislelizumab Versus Long-Course Chemoradiotherapy Plus Tislelizumab for Locally Advanced Rectal Cancer
- Sponsor
- Fujian Cancer Hospital (Government)
- Enrolment
- 130 planned
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Modified Short-course radiotherapy; Long-course radiotherapy; Oxaliplatin; Capecitabine; Tislelizumab; Capecitabine; Tislelizumab
- Ages
- adults, older adults
- Registry
- NCT07469306
Full record on ClinicalTrials.gov
From the registry
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
Primary outcomes
- Complete Response (CR) Rate
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered